Biopharmaceutics plays a pivotal role in the pharmaceutical industry, especially concerning generic drugs. Unlike traditional pharmaceuticals, generic drugs are bioequivalent alternatives to their brand-name counterparts, delivering the same therapeutic effects and safety profiles. The study of biopharmaceutics focuses on understanding the intricate interplay between the drug formulation, its absorption, distribution, metabolism, and excretion within the human body.
In the realm of generic drugs, biopharmaceutics becomes a critical factor in ensuring that the generic version mirrors the performance of the original drug. This involves meticulous evaluation of factors such as dissolution rates, bioavailability, and pharmacokinetics. Through advanced techniques and research methodologies, biopharmaceutics contributes to the development of high-quality generic drugs, promoting accessibility and affordability in healthcare.
Furthermore, biopharmaceutics aids in optimizing drug delivery systems, enhancing the efficiency of drug absorption, and minimizing potential side effects. As the pharmaceutical landscape evolves, the synergy between biopharmaceutics and generic drugs continues to drive advancements, fostering innovation and expanding treatment options for a global patient population.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia